Newcastle disease virus-modified autologous tumor cell vaccine (ATV-NDV)

Newcastle disease virus-modified autologous tumor cell vaccine (ATV-NDV) is a personalized cancer immunotherapy designed to stimulate a systemic anti-tumor immune response. The therapy involves harvesting a patient's own tumor cells, infecting them ex vivo with a non-lytic or lytic strain of Newcastle disease virus (NDV), and then re-administering the modified cells as a vaccine. NDV is an avian paramyxovirus that exhibits natural oncolytic properties, selectively replicating in human cancer cells due to their impaired antiviral interferon responses (Zamarin & Palese, 2014, Sci Transl Med). By using the whole tumor cell, the vaccine exposes the immune system to the full repertoire of individual neoantigens, while the viral infection provides the necessary 'danger signals' to overcome tumor-induced immunosuppression. This approach has been investigated in numerous clinical trials for solid tumors, including glioblastoma and colorectal cancer, where it has demonstrated the ability to induce long-term memory T-cell responses and improve overall survival in specific patient subsets. Unlike standard chemotherapy, ATV-NDV is characterized by a favorable safety profile, with side effects typically limited to transient flu-like symptoms.

Other names

Autologous tumor cell vaccine modified by Newcastle disease virusNDV-modified ATVMTH-68IO-VACNewcastle disease virus-infected autologous tumor cellsPV701-modified tumor vaccine

The vaccine functions by presenting a complete profile of patient-specific tumor-associated antigens (TAAs) in a highly immunogenic context. Newcastle disease virus (NDV) acts as a potent biological adjuvant by infecting the autologous tumor cells, which introduces viral pathogen-associated molecular patterns (PAMPs) such as double-stranded RNA. These PAMPs are recognized by host pattern recognition receptors like RIG-I, triggering the production of type I interferons (IFN-alpha/beta) and other pro-inflammatory cytokines (Schirrmacher, 2016, PubMed: 27417663). This inflammatory environment promotes the maturation of dendritic cells, enhances the cross-presentation of tumor antigens, and activates tumor-specific CD4+ and CD8+ T-cells, effectively breaking the immunological tolerance typically maintained by the tumor microenvironment (Fournier et al., 2013, Expert Opin Biol Ther).